The Nore1b/Mst1 Complex Restrains Antigen Receptor-Induced Proliferation of Naïve T Cells

Total Page:16

File Type:pdf, Size:1020Kb

The Nore1b/Mst1 Complex Restrains Antigen Receptor-Induced Proliferation of Naïve T Cells The Nore1B/Mst1 complex restrains antigen receptor-induced proliferation of naïve T cells Dawang Zhoua,b, Benjamin D. Medoffc,d, Lanfen Chene, Lequn Lif, Xian-feng Zhanga,b, Maria Praskovaa,b, Matthew Liua,b, Aimee Landryg, Richard S. Blumberge, Vassiliki A. Boussiotisf,h, Ramnik Xavierg,i, and Joseph Avrucha,b,1 aDepartment of Molecular Biology and the bDiabetes, cPulmonary and Critical Care, iGastrointestinal, and hHematology and Oncology Units of the Medical Services, dCenter for Immunology and Inflammatory Diseases, gCenter for Computational and Integrative Biology and fDivision for Surgical Services, Cancer Center of the Massachusetts General Hospital; and eDivision of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Department of Medicine, Harvard Medical School, Boston, MA 02114 Communicated by John T. Potts Jr., Massachusetts General Hospital, Charlestown, MA, October 27, 2008 (received for review May 16, 2008) The Mst1 and Mst2 protein kinases are the mammalian homologs facilitated by the binding of both kinases to the noncatalytic of hippo, a major inhibitor of cell proliferation in Drosophila. Mst1 scaffold protein salvador/shar-pei; hippo also phosphorylates the is most abundant in lymphoid tissues. Mice lacking Mst1 exhibit noncatalytic protein MATS, which then binds to warts/LATS, markedly reduced levels of the Mst1 regulatory protein Nore1B/ promoting its autophosphorylation and activation. Activated RAPL in lymphoid cells, whereas Mst2 abundance is unaltered. warts, in turn, phosphorylates and negatively regulates the Mst1-null mice exhibit normal T cell development but low numbers transcriptional coactivator yorkie. Loss of hippo, warts/LATS, of mature naïve T cells with relatively normal numbers of effector/ Salvador, or MATS each results in overgrowth of a similar memory T cells. In vitro, the Mst1-deficient naïve T cells exhibit nature, whereas yorkie loss-of-function reduces growth and is markedly greater proliferation in response to stimulation of the T epistatic to the other components. Studies in mammalian sys- cell receptor whereas the proliferative responses of the Mst1-null tems indicate that this pathway is largely conserved; LATS1 (18) effector/memory T cell cohort is similar to wild type. Thus, elimi- and MOBKL1A/B (19), the mammalian orthologs of warts/ nation of Mst1 removes a barrier to the activation and proliferative LATS and MATS, are Mst1/2 substrates and negative regulators response of naïve T cells. The levels of Mst1 and Nore1B/RAPL in of cell proliferation (19, 20). Moreover, mice lacking LATS1 wild-type effector/memory T cells are approximately 10% those develop soft tissue sarcomas and ovarian tumors (21). Recipro- seen in wild-type naïve T cells, which may contribute to the cally, YAP, a mammalian homolog of yorkie, is phosphorylated enhanced proliferative responses of the former. Freshly isolated and negatively regulated by LATS1 (22–24). YAP is amplified in Mst1-null T cells exhibit high rates of ongoing apoptosis, a likely a wide variety of murine and human tumors (25); overexpression basis for their low numbers in vivo; they also exhibit defective of YAP transforms mammary epithelial cells in vitro (25) and clustering of LFA-1, as previously observed for Nore1B/RAPL- produces hyperplasia and cancer in mouse liver (22, 26). As deficient T cells. Among known Mst1 substrates, only the phos- regards other outputs, Mst1 activated by oxidant stress phos- phorylation of the cell cycle inhibitory proteins MOBKL1A/B is lost phorylates the Foxo1/3a polypeptides in their forkhead domain, CELL BIOLOGY entirely in TCR-stimulated, Mst1-deficient T cells. Mst1/2-catalyzed disrupting 14–3-3 binding and inhibiting the ability of Akt to MOBKL1A/B phosphorylation slows proliferation and is therefore promote Foxo1/3a nuclear exit (27). a likely contributor to the anti-proliferative action of Mst1 in naïve To define more fully the physiologic roles of Mst1, we gen- T cells. The Nore1B/RAPL-Mst1 complex is a negative regulator of erated mice lacking Mst1 polypeptide expression. naïve T cell proliferation. Results Mst1-Deficient Lymphoid Cells Exhibit Much Lower Nore1B Polypep- Mob1 ͉ Mst1 knockout ͉ RAPL ͉ hippo ͉ Stk4 tide but Unaltered Mst2. Mice lacking Mst1 polypeptide expression were generated from an ES cell line bearing a gene trap inserted st1 and Mst2 are closely related mammalian class II GC between the first and second exons (see supporting information Mprotein (ser/thr) kinases (1) whose overexpression induces (SI) Fig. S1). Mst1-deficient mice survive development, are apoptosis in many transformed cell lines through a combination fertile, and appear unremarkable. Mst1 is expressed at greatest of p53- and Jnk-dependent pathways (2–4). Regarding the abundance in lymphoid organs (Fig. 1A); lymphocytes from the physiological roles of these kinases, Kinashi and colleagues Mst1 trap/trap mice (henceforth called Mst1Ϫ/Ϫ) lack Mst1 demonstrated that the ability of ␣CD3/␣CD28 and chemokines polypeptide but show unaltered levels of Mst2 (Fig. 1B Left). to promote the Rap1-GTP-dependent integrin clustering nec- Mst1 can be coprecipitated with rassf family polypeptides (9); in essary for T cell adhesion and migration (5) is strongly depen- lymphocytes, the Rassf5 isoform Nore1B/RAPL, a Ras-Rap- dent on Mst1 (6), which is proposed to be activated through the binding protein, is a major Mst1 partner (6). Surprisingly, the Rap1-GTP recruitment of a Nore1B (also called RAPL)/Mst1 level of the Nore1B/RAPL polypeptide is greatly diminished in complex to the immunological synapse (7). The Mst1 sub- the Mst1-null lymphocytes (Fig. 1B Left) despite unaltered strate(s) that mediate this response is (are) not known. Mst1 and Mst2 are found in constitutive complexes with members of the Rassf polypeptide family (8, 9), at least two of which, RASSF1A Author contributions: D.Z., B.D.M., L.L., R.S.B., V.A.B., R.X., and J.A. designed research; D.Z., and Nore1A/RASSF5, are well established tumor suppressors B.D.M., L.C., L.L., M.L., A.L., and R.X. performed research; X.Z. and M.P. contributed new reagents/analytic tools; D.Z., B.D.M., L.C., L.L., R.S.B., V.A.B., R.X., and J.A. analyzed data; (10). Nevertheless, direct evidence in support of a tumor sup- and D.Z., B.D.M., R.X., and J.A. wrote the paper. pressor function for Mst1 and/or Mst2 is not yet available. The authors declare no conflict of interest. Mst1 and Mst2 resemble most closely the drosophila protein Freely available online through the PNAS open access option. kinase hippo and human Mst2 can complement hippo deficiency 1To whom correspondence should be addressed at: Department of Molecular Biology, (11). Loss of hippo function results in massive overgrowth of the Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114. E-mail: fly eye, due to an acceleration of cell proliferation together with [email protected]. a deficit in developmental apoptosis (11–14). The pathway This article contains supporting information online at www.pnas.org/cgi/content/full/ downstream of hippo has been extensively described (15–17). 0810773105/DCSupplemental. Hippo phosphorylates the protein kinase warts/LATS, which is © 2008 by The National Academy of Sciences of the USA www.pnas.org͞cgi͞doi͞10.1073͞pnas.0810773105 PNAS ͉ December 23, 2008 ͉ vol. 105 ͉ no. 51 ͉ 20321–20326 Downloaded by guest on September 23, 2021 Peripheral blood Spleen A CD4+ A B 25 40 * CD4+/CD62L+ CD4+ * CD4+/ CD8+/ muscle CD8+/ 30 CD8+ CD62L+ CD62L+ CD8+ CD62L+ CD4+/ * CD4+/ * stomach intestine liver lung thymus skin heart * Skel marrow lymph node cortex cerebellum kidney spleen 20 CD44+ CD8+/ CD44+ CD8+/ -Mst1 * CD44+ * 10 * CD44+ -Mst2 0 % total cells % total lymphocytes 6 CD4+ CD4+ l) 14 -Nore1B 3.5 * * CD4+/ / CD4+/CD62L+ 12 3 3 * CD8+ CD62L+ CD8+/ 2.5 CD8+/ 10 * CD8+ CD4+/ * CD62L+ -Mob1 2 CD62L+ 8 * * CD8+/ 6 CD44+ * 1.5 CD4+/ CD8+/ * 4 CD44+ -Actin 1 CD44+ CD44+ 0.5 Total cells X 10 2 0 Total cells (x10 B spleen spleen C +/+ +/- -/- +/+ -/- vector + - - Flag-MST1-WT C 17.45 24.08 11.27 -Mst1 - + - * * Flag-MST1-K59R Mst1 MST1- -28s - - + 3 -Nore1B Nore1B Nore1B- + + + * WT -Mob1 -18s 2 58.25 -Flag 21.33 -Rassf1C 1 CD8 CD44 47.90 12.07 -Mst2 -Nore1B 7.37 -28s Mst1 -Actin -Actin 0 -18s CD4 mRNA (KO/WT) er null liv 32.98 lung colon heart 18.08 Fig. 1. Characterization of Mst1-null mice. (A) Expression of Mst1, Mst2 and intestine stomach CD4 CD62L some other relevant polypeptides in mouse tissues. Mst1/2, Nore1B, and Mob1 expression in mouse organs were analyzed by immunoblot and anti-actin Fig. 2. Peripheral T cell cohorts in wild-type and Mst1-deficient mice. (A)T served as a loading control. (B) Polypeptide and mRNA expression in spleen lymphocytes in the blood of wild-type and Mst1-null mice. The number of ϩ ϩ ϩ ϩ from wild-type and Mst1 gene trap mice. Left, Immunoblot of spleen extracts CD4 , CD8 , and naïve CD4 and CD8 T cells in the peripheral blood of for the polypeptides indicated. Right, Northern blot of splenic RNA. 18S and Mst1-null mice compared with wild-type mice (n ϭ 4 pairs of Mst1-null and 28S ribosomal RNAs serve as internal controls. (C) The Mst1 polypeptide wild-type littermates). Asterisks in this and all subsequent figures indicates a enhances the level of coexpressed Nore1B/RAPL. Vector encoding FLAG- P Ͻ 0.05 or lower calculated from a two-tailed Student t test. Black bars are tagged Nore1B was cotransfected in HEK293 cells with empty vector or vector Mst1ϩ/ϩ and white bars are Mst1Ϫ/Ϫ in this and all later figures. (B) T cell encoding FLAG-Mst1(WT) or FLAG-Mst1(K59R). An immunoblot of the ex- populations in the Mst1-null and wild-type spleen.
Recommended publications
  • Correlation of Cytokine Level with the Severity of Severe Fever With
    Liu et al. Virology Journal (2017) 14:6 DOI 10.1186/s12985-016-0677-1 RESEARCH Open Access Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome Miao-Miao Liu1, Xiao-Ying Lei1, Hao Yu2, Jian-zhi Zhang3 and Xue-jie Yu1,4* Abstract Background: Severe fever with thrombocytopenia syndrome (SFTS) was an emerging hemorrhagic fever that was caused by a tick-borne bunyavirus, SFTSV. Although SFTSV nonstructural protein can inhibit type I interferon (IFN-I) production Ex Vivo and IFN-I played key role in resistance SFTSV infection in animal model, the role of IFN-I in patients is not investigated. Methods: We have assayed the concentration of IFN-α, a subtype of IFN-I as well as other cytokines in the sera of SFTS patients and the healthy population with CBA (Cytometric bead array) assay. Results: The results showed that IFN-α, tumor necrosis factor (TNF-α), granulocyte colony-stimulating factor (G-CSF), interferon-γ (IFN-γ), macrophage inflammatory protein (MIP-1α), interleukin-6 (IL-6), IL-10, interferon-inducible protein (IP-10), monocyte chemoattractant protein (MCP-1) were significantly higher in SFTS patients than in healthy persons (p < 0.05); the concentrations of IFN-α, IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10 were significant higher in severe SFTS patients than in mild SFTS patients (p < 0.05). Conclusion: The concentration of IFN-α as well as other cytokines (IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10) is correlated with the severity of SFTS, suggesting that type I interferon may not be significant in resistance SFTSV infection in humans and it may play an import role in cytokine storm.
    [Show full text]
  • MST1 Is a Key Regulator of Beta Cell Apoptosis and Dysfunction in Diabetes
    ARTICLES MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes Amin Ardestani1, Federico Paroni1,6, Zahra Azizi1,6, Supreet Kaur1,6, Vrushali Khobragade1, Ting Yuan1, Thomas Frogne2, Wufan Tao3, Jose Oberholzer4, Francois Pattou5, Julie Kerr Conte5 & Kathrin Maedler1 Apoptotic cell death is a hallmark of the loss of insulin-producing beta cells in all forms of diabetes mellitus. Current treatments fail to halt the decline in functional beta cell mass, and strategies to prevent beta cell apoptosis and dysfunction are urgently needed. Here, we identified mammalian sterile 20–like kinase-1 (MST1) as a critical regulator of apoptotic beta cell death and function. Under diabetogenic conditions, MST1 was strongly activated in beta cells in human and mouse islets and specifically induced the mitochondrial-dependent pathway of apoptosis through upregulation of the BCL-2 homology-3 (BH3)-only protein BIM. MST1 directly phosphorylated the beta cell transcription factor PDX1 at T11, resulting in the latter’s ubiquitination and degradation and thus in impaired insulin secretion. MST1 deficiency completely restored normoglycemia, beta cell function and survival in vitro and in vivo. We show MST1 as a proapoptotic kinase and key mediator of apoptotic signaling and beta cell dysfunction and suggest that it may serve as target for the development of new therapies for diabetes. Pancreatic beta cell death is the fundamental cause of type 1 diabetes of events, which makes the initiation of beta cell death complex and (T1D) and a contributing factor to the reduced beta cell mass in type 2 its blockade difficult to successfully achieve in vivo.
    [Show full text]
  • The Act of Controlling Adult Stem Cell Dynamics: Insights from Animal Models
    biomolecules Review The Act of Controlling Adult Stem Cell Dynamics: Insights from Animal Models Meera Krishnan 1, Sahil Kumar 1, Luis Johnson Kangale 2,3 , Eric Ghigo 3,4 and Prasad Abnave 1,* 1 Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone, Gurgaon-Faridabad Ex-pressway, Faridabad 121001, India; [email protected] (M.K.); [email protected] (S.K.) 2 IRD, AP-HM, SSA, VITROME, Aix-Marseille University, 13385 Marseille, France; [email protected] 3 Institut Hospitalo Universitaire Méditerranée Infection, 13385 Marseille, France; [email protected] 4 TechnoJouvence, 13385 Marseille, France * Correspondence: [email protected] Abstract: Adult stem cells (ASCs) are the undifferentiated cells that possess self-renewal and differ- entiation abilities. They are present in all major organ systems of the body and are uniquely reserved there during development for tissue maintenance during homeostasis, injury, and infection. They do so by promptly modulating the dynamics of proliferation, differentiation, survival, and migration. Any imbalance in these processes may result in regeneration failure or developing cancer. Hence, the dynamics of these various behaviors of ASCs need to always be precisely controlled. Several genetic and epigenetic factors have been demonstrated to be involved in tightly regulating the proliferation, differentiation, and self-renewal of ASCs. Understanding these mechanisms is of great importance, given the role of stem cells in regenerative medicine. Investigations on various animal models have played a significant part in enriching our knowledge and giving In Vivo in-sight into such ASCs regulatory mechanisms. In this review, we have discussed the recent In Vivo studies demonstrating the role of various genetic factors in regulating dynamics of different ASCs viz.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0023954 A1 Wu Et Al
    US 2015 0023954A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0023954 A1 Wu et al. (43) Pub. Date: Jan. 22, 2015 (54) POTENTIATING ANTIBODY-INDUCED GOIN33/574 (2006.01) COMPLEMENT-MEDIATED CYTOTOXCITY A613 L/4745 (2006.01) VAPI3K INHIBITION A613 L/4375 (2006.01) (52) U.S. Cl. (71) Applicant: MEMORIAL SLOAN-KETTERING CPC ....... A6IK39/39558 (2013.01); A61 K3I/4745 CANCER CENTER, New York, NY (2013.01); A61 K39/00II (2013.01); A61 K (US) 39/385 (2013.01); A61K31/4375 (2013.01); A6IK3I/5377 (2013.01); A61K.39/39 (72) Inventors: Xiaohong Wu, Forest Hills, NY (US); (2013.01); GOIN33/57484 (2013.01); CI2O Wolfgang W. Scholz, San Diego, CA I/6886 (2013.01); A61 K 2039/505 (2013.01); (US); Govind Ragupathi, New York, C12O 2600/16 (2013.01); C12O 2600/106 NY (US); Philip O. Livingston, (2013.01); A61K 2039/545 (2013.01) Bluffton, SC (US) USPC .................. 424/133.1; 424/277.1; 424/193.1; 424f1 74.1436/5O1435/7.1 : 506/9:435/7.92: (21) Appl. No.: 14/387,153 s s 435/6.12. 436/94 (22) PCT Filed: Mar. 14, 2013 (57) ABSTRACT (86). PCT No.: PCT/US 13/31278 Methodologies and technologies for potentiating antibody S371 (c)(1), based cancer treatments by increasing complement-mediated (2) Date: Sep. 22, 2014 cell cytotoxicity are disclosed. Further provided are method O O ologies and technologies for overcoming ineffective treat Related U.S. Application Data ments correlated with and/or caused by sub-lytic levels of (60) Provisional application No.
    [Show full text]
  • Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications
    International Journal of Molecular Sciences Review Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications Sandra Maria Barbalho 1,2,3,* , Uri Adrian Prync Flato 1,2 , Ricardo José Tofano 1,2, Ricardo de Alvares Goulart 1, Elen Landgraf Guiguer 1,2,3 , Cláudia Rucco P. Detregiachi 1 , Daniela Vieira Buchaim 1,4, Adriano Cressoni Araújo 1,2 , Rogério Leone Buchaim 1,5, Fábio Tadeu Rodrigues Reina 1, Piero Biteli 1, Daniela O. B. Rodrigues Reina 1 and Marcelo Dib Bechara 2 1 Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marilia (UNIMAR), Avenue Hygino Muzzy Filho, 1001, Marília 17525-902, São Paulo, Brazil; urifl[email protected] (U.A.P.F.); [email protected] (R.J.T.); [email protected] (R.d.A.G.); [email protected] (E.L.G.); [email protected] (C.R.P.D.); [email protected] (D.V.B.); [email protected] (A.C.A.); [email protected] (R.L.B.); [email protected] (F.T.R.R.); [email protected] (P.B.); [email protected] (D.O.B.R.R.) 2 School of Medicine, University of Marília (UNIMAR), Avenida Higino Muzzi Filho, 1001, Marília 17506-000, São Paulo, Brazil; [email protected] 3 Department of Biochemistry and Nutrition, Food Technology School, Marília 17525-902, São Paulo, Brazil 4 Medical School, University Center of Adamantina (UniFAI), Adamantina 17800-000, São Paulo, Brazil 5 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo (FOB–USP), Alameda Doutor Octávio Pinheiro Brisolla, 9-75, Bauru 17012901, São Paulo, Brazil * Correspondence: [email protected]; Tel.: +55-14-99655-3190 Received: 6 May 2020; Accepted: 19 May 2020; Published: 20 May 2020 Abstract: Skeletal muscle is capable of secreting different factors in order to communicate with other tissues.
    [Show full text]
  • MAPK and Hippo Signaling Pathways Crosstalk Via the RAF-1/MST-2 Interaction in Malignant Melanoma
    ONCOLOGY REPORTS 38: 1199-1205, 2017 MAPK and Hippo signaling pathways crosstalk via the RAF-1/MST-2 interaction in malignant melanoma RUizheng Feng1, JUnSheng gong1, LinA WU2, LEI WANG3, BAoLin zhAng1, GANG LIANG2, hUixiA zheng2 and hong xiAo2 Departments of 1Plastic Surgery and 2Pathology, The First hospital of Shanxi Medical University, Taiyuan, Shanxi 030024; 3Department of Gerontology, Shanxi Dayi Hospital, Taiyuan, Shanxi 030000, P.R. China Received november 11, 2016; Accepted June 14, 2017 DOI: 10.3892/or.2017.5774 Abstract. The aim of the present study was to expound on sible for over 80% of all skin cancer-related deaths. In 2012, the interactions between the mitogen-activated protein kinase 232,000 new cases of melanoma and 55,000 melanoma-related (MAPK) and Hippo pathway members, and to further eluci- deaths were reported worldwide (1). Moreover, the incidence date the molecular mechanisms of melanoma tumorigenesis. of melanoma is increasing at a rate faster than that of any other Four melanoma cell lines (C32, HS695T, SK-MEL-28 and solid tumor, and is thought to be the highest in white-skinned A375) were used in the present study. Western blotting was people living at low latitudes (2). In its advanced stages, mela- used to assess the expression levels of the MAPK and Hippo noma is highly malignant, owing to its potential for distant pathway effector proteins: rapidly accelerated fibrosarcoma-1 metastasis (3), and an extremely low 5-year survival rate proto-oncogene, serine/threonine kinase (RAF-1); serine/thre- (5-16%) (4). Unfortunately, melanoma is refractory to conven- onine kinase 3 (STK3; also known as MST-2); yes-associated tional chemotherapeutics, thus, the treatment options for protein (YAP); and tafazzin (TAZ).
    [Show full text]
  • SAV1 Promotes Hippo Kinase Activation Through Antagonizing the PP2A Phosphatase STRIPAK
    RESEARCH ARTICLE SAV1 promotes Hippo kinase activation through antagonizing the PP2A phosphatase STRIPAK Sung Jun Bae1†, Lisheng Ni1†, Adam Osinski1, Diana R Tomchick2, Chad A Brautigam2,3, Xuelian Luo1,2* 1Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, United States; 2Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, United States; 3Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, United States Abstract The Hippo pathway controls tissue growth and homeostasis through a central MST- LATS kinase cascade. The scaffold protein SAV1 promotes the activation of this kinase cascade, but the molecular mechanisms remain unknown. Here, we discover SAV1-mediated inhibition of the PP2A complex STRIPAKSLMAP as a key mechanism of MST1/2 activation. SLMAP binding to autophosphorylated MST2 linker recruits STRIPAK and promotes PP2A-mediated dephosphorylation of MST2 at the activation loop. Our structural and biochemical studies reveal that SAV1 and MST2 heterodimerize through their SARAH domains. Two SAV1–MST2 heterodimers further dimerize through SAV1 WW domains to form a heterotetramer, in which MST2 undergoes trans-autophosphorylation. SAV1 directly binds to STRIPAK and inhibits its phosphatase activity, protecting MST2 activation-loop phosphorylation. Genetic ablation of SLMAP in human cells leads to spontaneous activation of the Hippo pathway and alleviates the need for SAV1 in Hippo signaling. Thus, SAV1 promotes Hippo activation through counteracting the STRIPAKSLMAP PP2A *For correspondence: phosphatase complex. [email protected] DOI: https://doi.org/10.7554/eLife.30278.001 †These authors contributed equally to this work Competing interests: The Introduction authors declare that no The balance between cell division and death maintains tissue homeostasis of multicellular organisms.
    [Show full text]
  • Mutual Regulation Between Hippo Signaling and Actin Cytoskeleton
    Protein Cell 2013, 4(12): 904–910 DOI 10.1007/s13238-013-3084-z Protein & Cell REVIEW Mutual regulation between Hippo signaling and actin cytoskeleton Yurika Matsui1, Zhi-Chun Lai1,2,3 1 I ntercollege Graduate Degree Program in Cell and Developmental Biology, The Pennsylvania State University, University Park, PA 16802, USA 2 Department of Biology, The Pennsylvania State University, University Park, PA 16802, USA 3 Department of Biochemistry and Molecular Biology, The Pennsylvania State University, University Park, PA 16802, USA Correspondence: [email protected] Received September 12, 2013 Accepted October 21, 2013 Cell & ABSTRACT core components are Hippo (Hpo, Mst1, and Mst2 in verte- brates), Salvador (Sav, Sav1, or WW45 in vertebrates), Warts Hippo signaling plays a crucial role in growth control and (Wts, Lats1, and Lats2 in vertebrates), and Mob as tumor sup- tumor suppression by regulating cell proliferation, apop- Protein pressor (Mats, MOBKL1a, and MOBKL1b in vertebrates). In tosis, and differentiation. How Hippo signaling is regulat- receiving a signal from the upstream regulators, Hpo (Mst1/2) ed has been under extensive investigation. Over the past phosphorylates Wts (Lats1/2) with the assistance of a scaf- three years, an increasing amount of data have supported folding protein, Sav (Sav1). This phosphorylation activates the a model of actin cytoskeleton blocking Hippo signaling kinase activity of Wts (Lats1/2), and along with its adaptor Mats activity to allow nuclear accumulation of a downstream (MOBKL1a/MOBKL1b), Wts (Lats1/2) phosphorylates Yorkie effector, Yki/Yap/Taz. On the other hand, Hippo signaling (Yki, Yap/Taz in vertebrates). 14-3-3 proteins interact with the negatively regulates actin cytoskeleton organization.
    [Show full text]
  • Antigen-Specific Induced Foxp3 Regulatory T Cells Are Generated
    Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade Ivana R. Ferrer, Maylene E. Wagener, Minqing Song, Allan D. Kirk, Christian P. Larsen, and Mandy L. Ford1 Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA 30322 Edited by James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, and approved November 4, 2011 (received for review April 7, 2011) Blockade of the CD40/CD154 pathway potently attenuates T-cell in vivo accumulation of Treg and deletion of graft-specific ef- responses in models of autoimmunity, inflammation, and trans- fectors after CD40/CD154 blockade has not been investigated. plantation. Indeed, CD40 pathway blockade remains one of the To address these questions, we used an ovalbumin (OVA)- most powerful methods of prolonging graft survival in models of expressing transgenic mouse model (20), which allowed us to di- + + transplantation. But despite this effectiveness, the cellular and rectly track both donor-reactive CD4 and CD8 T-cell responses molecular mechanisms underlying the protective effects of CD40 simultaneously over time. Although previous studies have used pathway blockade are incompletely understood. Furthermore, the transgenic models to assess the degree of T-cell deletion after CD154/CD40 blockade (16, 21), none has systematically inter- relative contributions of deletion, anergy, and regulation have not + been measured in a model in which donor-reactive CD4+ and CD8+ rogated the impact of anti-CD154 on the kinetics of both CD4 and CD8+ T-cell deletion and acquisition of effector function. T-cell responses can be assessed simultaneously. To investigate the fi Our results indicated that although CD40/CD154 blockade alone impact of CD40/CD154 pathway blockade on graft-speci c T-cell delayed donor-reactive CD4+ and CD8+ T-cell expansion and responses, a transgenic mouse model was used in which recipients differentiation, the addition of DST was required for antigen- fi + + containing ovalbumin-speci cCD4 and CD8 TCR transgenic T specific T-cell deletion.
    [Show full text]
  • Human CD154 (CD40 Ligand) Recombinant Protein Catalog Number: 14-8502 Also Known As:CD40L, CD40-L RUO: for Research Use Only
    Human CD154 (CD40 Ligand) Recombinant Protein Catalog Number: 14-8502 Also Known As:CD40L, CD40-L RUO: For Research Use Only Product Information Contents: Human CD154 (CD40 Ligand) Recombinant Protein Formulation: Sterile liquid: phosphate buffered saline, pH 7.2, Catalog Number: 14-8502 1.0% BSA. 0.22 µm filtered. Handling Conditions: For best recovery, quick-spin vial prior to Temperature Limitation: Store at less than or equal to -70°C. opening. Use in a sterile environment Batch Code: Refer to Vial Source: E. coli Use By: Refer to Vial Purity: Greater than 98%, as determined by SDS-PAGE Endotoxin Level: Less than 0.01 ng/ug cytokine as determined by the LAL assay. Bioactivity: The ED50 measured in a T-47D cell line proliferation assay is typically 40 ng/ml, corresponding to a specific activity of approximately 2.5 x104 Units/mg. Description CD40 ligand, (CD40L, also known as CD154, TRAP or gp39) is a membrane glycoprotein expressed on activated CD4+ T-cells, NK cells, mast cells, basophils and eosinophils. The CD40-CD40L interaction stimulates B cell immune response which includes cell surface antigen expression, cell cycle activation, Ig isotype switching, Ig secretion and memory generation. The CD40-CD40L interaction also plays important roles in monocyte and dendritic cell activation, T-cell co-stimulation and cytokine production. It has been reported that the CD40-CD40L interaction is involved in the pathogenesis of amyloid pathology in Alzheimer disease. Recombinant Human CD40L produced in E.Coli is a non-glycosylated, polypeptide containing 149 amino acids and having a molecular mass of 16 kDa.
    [Show full text]
  • High Sensitivity Immunoassays for Detecting Ifn-Gamma in Cytokine Release Syndrome
    APPLICATION NOTE HIGH SENSITIVITY IMMUNOASSAYS FOR DETECTING IFN-GAMMA IN CYTOKINE RELEASE SYNDROME INTRODUCTION T cell expansion with increased Interferon Gamma (IFN-γ) release. Note that increased IFN-γ is also an early and prominent element of CRS. IFN , along with IL-6, IL-10 and TNF-alpha are the Cytokine Release Syndrome (CRS), also known as the “Cytokine -γ core cytokines involved in CRS (2). IFN activates macrophages Storm”, is a systemic inflammatory response characterized at the -γ which secrete excessive amounts of other cytokines such as cellular level by the rapid release of excessive concentrations IL-6, TNF and IL-10. Lastly, it is important to keep in mind that of cytokines (1,2). Patient symptoms range from mild fever to α IFN is pleiotropic and has both harmful and beneficial effects. hypotension, multiorgan system failure, neurotoxicity and death. -γ Although IFN has a harmful role in CRS, it also been correlated CRS is caused by a variety of events, including viral infection, -γ with antiproliferative, proapoptotic and antitumor activities in the antibody-based immunotherapy and cellular immunotherapy. context of cancer (4). In antibody-based immunotherapies, the incidence of CRS is relatively low, however, onset can occur within days and up to We previously described the new 3rd generation R&D Systems® weeks of infusion in cellular immunotherapy. Evidence suggests IFN-γ Quantikine® ELISA kit. Learn more about that assay here. that the risk and severity of CRS is influenced by the type of Here, we describe the R&D Systems® Human IFN-γ Quantikine® therapy, disease burden and patient characteristics, such as age.
    [Show full text]
  • Hippo Signaling Pathway in Liver and Pancreas: the Potential Drug Target for Tumor Therapy
    http://informahealthcare.com/drt ISSN: 1061-186X (print), 1029-2330 (electronic) J Drug Target, Early Online: 1–9 ! 2014 Informa UK Ltd. DOI: 10.3109/1061186X.2014.983522 REVIEW ARTICLE Hippo signaling pathway in liver and pancreas: the potential drug target for tumor therapy Delin Kong*, Yicheng Zhao*, Tong Men, and Chun-Bo Teng College of life science, Northeast Forestry University, Harbin, China Abstract Keywords Cell behaviors, including proliferation, differentiation and apoptosis, are intricately controlled Cancer gene therapy, hepatic targeting, during organ development and tissue regeneration. In the past 9 years, the Hippo signaling in vitro model, tumor targeting pathway has been delineated to play critical roles in organ size control, tissue regeneration and tumorigenesis through regulating cell behaviors. In mammals, the core modules of the Hippo History signaling pathway include the MST1/2-LATS1/2 kinase cascade and the transcriptional co-activators YAP/TAZ. The activity of YAP/TAZ is suppressed by cytoplasmic retention due Received 5 September 2014 to phosphorylation in the canonical MST1/2-LATS1/2 kinase cascade-dependent manner or the Revised 21 October 2014 non-canonical MST1/2- and/or LATS1/2-independent manner. Hippo signaling pathway, which Accepted 29 October 2014 can be activated or inactivated by cell polarity, contact inhibition, mechanical stretch and Published online 3 December 2014 extracellular factors, has been demonstrated to be involved in development and tumorigenesis of liver and pancreas. In addition, we have summarized several small molecules currently available that can target Hippo-YAP pathway for potential treatment of hepatic and pancreatic cancers, providing clues for other YAP initiated cancers therapy as well.
    [Show full text]